ECE2016 Guided Posters Pituitary - Clinical (10 abstracts)
Plasma apelin concentrations in patients with polyuria-polydipsia syndrome
Sandrine Urwyler 1 , Katharina Timper 2 , Wiebke Fenske 3 , Nadia de Mota 4 , Anne Blanchard 5 , Felix Kühn 6 , Nica Frech 1 , Birsen Arici 7 , Jonas Ruthishauser 8 , Peter Kopp 9 , Christoph Stettler 6 , Beat Müller 10 , Mira Katan 11 , Catherine Llorens-Cortes 4 & Mirjam Christ-Crain 1
1Clinic of Endocrinology, Diabetes and Metabolism, Department of Clinical Research, University Hospital Basel, Basel, Switzerland; 2Max-Planck-Institute for Metabolism Research, Cologne, Germany; 3Integrated Research and Treatment Center for Adiposity Diseases, Leipzig University Medical Center, Medical Research Center Building, Leipzig, Germany; 4Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, CIRB, College de France, INSERM U1050, Paris, France; 5Assistance publique des hôpitaux de Paris, European Georges Pompidou Hospital, Clinical Investigation Center, Paris, France; 6Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Bern – Inselspital, Bern, Switzerland; 7Department of Internal Medicine, Spital Rheinfelden, Rheinfelden, Switzerland; 8University Clinic of Internal Medicine, Kantonsspital Baselland, Bruderholz, Bruderholz, Switzerland; 9Division of Endocrinology, Metabolism and Molecular Medicine and Center for Genetic Medicine, Northwestern University, Chicago, Illinois, USA; 10Division of Endocrinology, Diabetology and Metabolism, Medical University Clinic, Kantonsspital Aarau, Aarau, Switzerland; 11Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
Background: Apelin and arginine-vasopressin (AVP) are antagonists in the regulation of body fluid and osmotic homeostasis. So far there exist no data about apelin levels in patients with polyuria-polydipsia syndrome (PPS).
Methods: Plasma apelin and copeptin concentrations were measured in 15 patients with complete central diabetes insipidus (cDI), in seven patients with complete nephrogenic diabetes insipidus (nDI) and 19 patients with primary polydipsia (PP) and were compared to those in 113 healthy volunteers.
Results: Median plasma apelin levels were highest in patients with nDI (413 pmol/l (IQR 332; 504), P=0.01) and lower in patients with PP (190 pmol/l (172; 215), P<0.001) or cDI (209 pmol/l (174; 241), P=0.02) compared to healthy volunteers (254 pmol/l (225; 311)). Plasma apelin to copeptin ratio in patients with PP (53 pmol/pmol (38; 92), P>0.9) was similar to healthy volunteers (57 pmol/pmol (37; 102)). In contrast, apelin to copeptin ratio was higher in patients with cDI (89 pmol/pmol (73; 135), P=0.02) and lower in patients with nDI (7 pmol/pmol (6; 10), P<0.001) compared to healthy volunteers.
Conclusion: In PP, normal plasma apelin to copeptin ratio attests a normal water homeostasis. In contrast, in patients with cDI or nDI the increased or decreased apelin to copeptin ratio, respectively, reflects a disturbed osmotic and body fluid homeostasis.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more